Brevan Howard Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Brevan Howard Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.43M	Sell	102,768 -113,077	-52%	-$2.81M	0.03%	495
2026 Q1	$4.52M	Buy	215,845 +107,942	+100%	+$2.43M	0.04%	269
2025 Q4	$2.42M	Buy	107,903 +40,868	+61%	+$1.34M	0.03%	428
2025 Q3	$2.02M	Buy	67,035 +58,874	+721%	+$1.77M	0.01%	558
2025 Q2	$297K	Buy	+8,161	New	+$294K	﹤0.01%	1556
2025 Q1	–	Sell	-35,201	Closed	-$1.48M	–	1401
2024 Q4	$1.48M	Buy	35,201 +18,960	+117%	+$941K	0.01%	343
2024 Q3	$902K	Buy	+16,241	New	+$827K	0.01%	485
2024 Q2	–	Sell	-9,077	Closed	-$424K	–	1344
2024 Q1	$424K	Buy	+9,077	New	+$428K	﹤0.01%	511

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Brevan Howard Capital Management's RARE Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 52% in Q2 2026, selling an estimated $2.81M and leaving 102,768 shares worth $3.43M. The position accounts for 0.03% of the portfolio, ranked #495.

Brevan Howard Capital Management first reported a position in RARE in Q1 2024 and has held it in 8 quarters since. The position peaked at $4.52M in Q1 2026. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Brevan Howard Capital Management held 102,768 shares of Ultragenyx Pharmaceutical worth $3.43M as of Q2 2026.
Brevan Howard Capital Management sold 113,077 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $2.81M.
Ultragenyx Pharmaceutical made up 0.03% of Brevan Howard Capital Management's portfolio in Q2 2026, its #495 holding.
Brevan Howard Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and has held it in 8 quarters since.
Brevan Howard Capital Management's Ultragenyx Pharmaceutical position peaked at $4.52M in Q1 2026.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.